A real-world retrospective analysis linked the bispecific antibodies epcoritamab and glofitamab to somewhat poorer outcomes in relapsed or refractory large B-cell lymphoma compared to clinical trials. The study tracked 172 patients with a median follow-up of 5 months, finding median progression-free survival of 2.7 months and median overall survival of 7.2 months. Despite some patients responding well to treatment, outcomes were lower than in pivotal trials. Cytokine release syndrome occurred in 39.2% of patients, with higher rates in the epcoritamab group. Loss of CD20 expression was high in patients receiving bispecific therapy. Proper management of toxicities is crucial when using these drugs.
Source link
Bispecific Antibodies Fare Less Well in Real-World Analysis
